Logotype for Apollo Hospitals Enterprise Limited

Apollo Hospitals (APOLLOHOSP) Q1 25/26 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Apollo Hospitals Enterprise Limited

Q1 25/26 earnings summary

23 Nov, 2025

Executive summary

  • Consolidated revenue grew 15% year-on-year to INR 5,842 crore (₹58,421 million) in Q1 FY26, with EBITDA up 26% and PAT up 42%, reflecting strong performance across all divisions and digital expansion.

  • Healthcare Services revenue increased 11% year-on-year, driven by 3% inpatient volume growth and 9% higher average revenue per patient.

  • Strategic focus on clinical excellence, digital platform scaling, and hospital capacity expansion, with 4,300+ new beds planned over the next five years and 700 beds to be operational in FY26.

  • Announced demerger and reorganization of digital health and pharmacy business, with planned listing of New Co and Keimed merger by FY27.

  • Launched new digital and preventive health initiatives, including AI-powered platforms, expanded insurance offerings, and a central reference laboratory in Chennai.

Financial highlights

  • Healthcare Services revenue at INR 2,935 crore (up 11% YoY); insurance patient revenue up 13%, cash patient revenue up 16%.

  • Apollo HealthCo revenue at INR 2,472 crore (up 19% YoY); Apollo Health and Lifestyle revenue at INR 435 crore (up 19% YoY).

  • Consolidated EBITDA reached INR 852 crore (up 26% YoY); Healthcare Services EBITDA at INR 718 crore (up 15% YoY); Apollo Health and Lifestyle EBITDA at INR 40 crore (up 31% YoY).

  • Consolidated PAT was INR 433 crore, a 42% YoY increase; diluted EPS at INR 30.10 per share.

  • Net debt position improved to -₹3,429 million, with gross debt at ₹28,504 million and cash equivalents at ₹29,763 million.

Outlook and guidance

  • Digital business (Apollo 24/7) is on track to achieve breakeven by fiscal year-end.

  • Hospital business expects 13-14% organic growth in existing assets, with an additional 10% growth from new beds over the next 2-3 years.

  • Expansion strategy includes over 4,300 new beds in five years, with a total project cost of ~₹7,600 crore; first phase of 2,000 beds underway.

  • Apollo HealthCo and Keimed combined expected to reach INR 25,000 crore revenue and 7% EBITDA margin by FY27.

  • Ongoing evaluation of bolt-on acquisitions in Tier-1 cities and metros.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Apollo Hospitals